Achieve Life Sciences, Inc.
ACHV
$7.64
-$0.21-2.62%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
MarketBeat
9/9/2026
-
Tickeron - Stocks
9/4/2026
-
Tickeron - Stocks
9/3/2026
-
Globe Newswire
9/3/2026
-
TipRanks
9/3/2026
-
MarketBeat
9/3/2026
-
Tickeron - Stocks
9/3/2026
-
Tickeron - Stocks
9/2/2026
-
MarketBeat
9/1/2026
-
MarketBeat
8/29/2026
-
Tickeron - Stocks
8/28/2026
-
MarketBeat
8/27/2026
-
MarketBeat
8/24/2026
-
Simply Wall St
8/22/2026
-
The Cerbat Gem
8/21/2026
-
MarketBeat
8/21/2026
-
Tickeron - Stocks
Achieve Life Sciences (ACHV, $8.53) price may drop as it broke higher Bollinger Band on Aug 19, 2026
8/20/2026
-
Tickeron - Stocks
8/18/2026
-
The Cerbat Gem
8/17/2026
-
TipRanks
8/15/2026
-
MarketBeat
8/14/2026
-
TipRanks
8/14/2026
-
Simply Wall St
Achieve Life Sciences (ACHV, $7.25) price may drop as it broke higher Bollinger Band on Aug 13, 2026
8/14/2026
-
Tickeron - Stocks
8/14/2026
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, August 11, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 2 and 6 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
604 210 2217
Address
22722 29th Dr. SE
Suite 100
Bothell, WA 98021
Suite 100
Bothell, WA 98021
Country
Year Founded
--
Business Description
Sector
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The...
more